Photo from Kevin Conroy/LinkedIn
Jul 26, 2024, 19:50
Kevin Conroy: Katherine is an incredible reminder of the 20-year impact Oncotype DX has made on breast cancer
Kevin Conroy, Chairman and CEO at Exact Sciences, shared on LinkedIn:
“Our patients are at the heart of everything we do at Exact Sciences. Meet Katherine, our first-ever Oncotype DX Breast Recurrence Score test patient. I was thrilled to connect with her recently.
Katherine was diagnosed with breast cancer in 2004 and was able to forgo chemotherapy after receiving her test results. She’s an incredible reminder of the 20-year impact Oncotype DX has made on breast cancer and aiding in personalized treatment decisions.”
Source: Kevin Conroy/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 14:40
Nov 14, 2024, 14:39
Nov 14, 2024, 14:28
Nov 14, 2024, 14:05
Nov 14, 2024, 13:49